High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A

Cardiovascular Research

Volumn 94, Issue 1, 2012, Pages 154-162

  Tölle, Markus ^a   Huang, Tao ^a   Schuchardt, Mirjam ^a   Jankowski, Vera ^a   Prüfer, Nicole ^a   Jankowski, Joachim ^a   Tietge, Uwe J F ^b   Zidek, Walter ^a   Van Der Giet, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

End stage renal disease; High density lipoprotein; Pro inflammatory signalling; Serum amyloid A

Indexed keywords

FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; KIDNEY FAILURE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEOMICS; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINE CCL2; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENE EXPRESSION REGULATION; GERMANY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN BINDING; PROTEOMICS; RATS; RATS, WISTAR; RECEPTORS, FORMYL PEPTIDE; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84859093135     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs089     Document Type: Article

References (65)

1. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-772.
2. Brewer HB Jr. The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011;96:1246-1257.
3. Lee JM, Choudhury RP. Atherosclerosis regression and high-density lipoproteins. Expert Rev Cardiovasc Ther 2010;8:1325-1334.
4. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-1232.
5. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-135.
6. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009;284: 32336-32343.
7. Cockerill GW, Huehns TY,Weerasinghe A, Stocker C, Lerch PG, Miller NE et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108-112.
8. Dansky HM, Charlton SA, Barlow CB, Tamminen M, Smith JD, Frank JS et al. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest 1999;104:31-39.
9. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009;116:87-98.
10. Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol 2010;37:710-718.
11. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293-303.
12. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004;15:538-548.
13. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function: recent advances. J Am Coll Cardiol 2005;46:1792-1798.
14. Bevc S, SiabićS, Hojs R. Atherosclerosis in hemodialysis patients-the role of microinflammation. Ren Fail 2008;30:1012-1016.
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 1296-1305.
16. Drueke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 2010;6:723-735.
17. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
18. Parsy D, Dracon M, Cachera C, Parra HJ, Vanhoutte G, Tacquet A et al. Lipoprotein abnormalities in chronic haemodialysis patients. Nephrol Dial Transplant 1988;3:51-56.
19. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia- relation to renal function and dialysis. Nephron 1991;57:401-410.
20. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9: 2082-2088.
21. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007;72:1149-1156.
22. Saemann MD, Poglitsch M, Kopecky C, Haidinger M, Horl WH, Weichhart T. The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest 2010;40: 1131-1143.
23. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008;28: 1542-1548.
24. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
25. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004;15:145-149.
26. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004;14:161-165.
27. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-1339.
28. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353.
29. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 1978;90:420-426.
30. Jankowski V, Meyer AA, Schlattmann P, Gui Y, Zheng XL, Stamcou I et al. Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. Arterioscler Thromb Vasc Biol 2007;27:1776-1781.
31. Schuchardt M, Prüfer J, Prüfer N, Wiedon A, Huang T, Chebli M et al. The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y2-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation. J Mol Med (Berl) 2011;89:799-810.
32. Cai H, Song C, Endoh I, Goyette J, Jessup W, Freedman SB et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007;178:1852-1860.
33. Lee HY, Kim SD, Shim JW, Lee SY, Lee H, Cho KH et al. Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol 2008;181:4332-4339.
34. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009;61:119-161.
35. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, Lane WS et al. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 1992;267:3862-3867.
36. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acutephase reactant for clinical practice. Eur J Clin Invest 1996;26:427-435.
37. Witting PK, Song C, Hsu K, Hua S, Parry SN, Aran R et al. The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med 2011;51:1390-1398.
38. Kluve-Beckerman B, Drumm ML, Benson MD. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol 1991;10:651-661.
39. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389-403.
40. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55: 648-658.
41. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726-732.
42. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease - baseline findings of the PAIS project. Atherosclerosis 2001;156:451-456.
43. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 2008;148:85-93.
44. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-2767.
45. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994;180:203-209.
46. Chiba T, Chang MY,Wang S, Wight TN, McMillen TS, Oram JF et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol 2011;31:1326-1332.
47. Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-a, interleukin-1b, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 2000;268:405-408.
48. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, Tannock LR. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 2008;173:1902-1910.
49. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011;22:302-307.
50. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006;3:e287.
51. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986;261:9644-9651.
52. Kappelle PJ, de Boer JF, Perton FG, Annema W, de Vries R, Dullaart RP et al. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 2011; doi: 10.1111/j.1365-2362.2011. 02604.x.
53. Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L, Valente M et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 1978;8:S26-S30.
54. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22: 1631-1641.
55. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 2005;280:2954-2961.
56. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML et al. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem 2005;280:8031-8040.
57. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, Fu D et al. CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem 2010;285:8492-8506.
58. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR 4 agonist? 2008;83:1174-1180.
59. Niemi K, TeiriläL, Lappalainen J, Rajamäki K, Baumann MH, Öörni K et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol 2011;186:6119-6128.
60. Karlsson J, Fu H, Boulay F, Bylund J, Dahlgren C. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists. Biochem Pharmacol 2006;71:1488-1496.
61. Hu JY, Le Y, Gong W, Dunlop NM, Gao JL, Murphy PM et al. Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J Leukoc Biol 2001;70:155-161.
62. Bjork JM, Chen G, Smith AR, Hommer DW. Incentive-elicited mesolimbic activation and externalizing symptomatology in adolescents. J Child Psychol Psychiatry 2010;51: 827-837.
63. Jahangiri A, de Beer MC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009;29: 261-267.
64. de Beer MC, Webb NR, Whitaker NL, Wroblewski JM, Jahangiri A, van der Westhuyzen DR et al. SR-BI selective lipid uptake: subsequent metabolism of acute phase HDL. Arterioscler Thromb Vasc Biol 2009;29:1298-1303.
65. Annema W, Nijstad N, Tölle M, de Boer JF, Buijs RV, Heeringa P et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A2. J Lipid Res 2010;51:743-754.